Ex vivo Ikkβ ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis

• Published in: Cardiovascular research Vol. 117; no. 3; pp. 756 - 766
• Main Authors: Kizilay Mancini, Ozge, Huynh, David N, Menard, Liliane, Shum-Tim, Dominique, Ong, Huy, Marleau, Sylvie, Colmegna, Ines, Servant, Marc J
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 22.02.2021
• Subjects: Aged; Animals; Atherosclerosis - enzymology; Atherosclerosis - genetics; Atherosclerosis - immunology; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cellular Senescence; Coculture Techniques; Diabetes Mellitus, Type 2 - enzymology; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - immunology; Disease Models, Animal; Editor's Choice; Female; Humans; I-kappa B Kinase - antagonists & inhibitors; I-kappa B Kinase - genetics; I-kappa B Kinase - metabolism; Inflammation Mediators - metabolism; Lymphocyte Activation; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells - drug effects; Mesenchymal Stem Cells - enzymology; Mesenchymal Stem Cells - immunology; Mice; Mice, Inbred C57BL; Middle Aged; Myocardial Infarction - enzymology; Myocardial Infarction - immunology; Myocardial Infarction - surgery; Original; Phenotype; Protein Kinase Inhibitors - pharmacology; Secretome; Signal Transduction; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; IKK beta signalling; Mesenchymal stromal cells; Inflammation; Immunopotency
• ISSN: 0008-6363; 1755-3245
• DOI: 10.1093/cvr/cvaa118

Abstract Aims Diabetes is a conventional risk factor for atherosclerotic cardiovascular disease and myocardial infarction (MI) is the most common cause of death among these patients. Mesenchymal stromal cells (MSCs) in patients with type 2 diabetes mellitus (T2DM) and atherosclerosis have impaired ability to suppress activated T-cells (i.e. reduced immunopotency). This is mediated by an inflammatory shift in MSC-secreted soluble factors (i.e. pro-inflammatory secretome) and can contribute to the reduced therapeutic effects of autologous T2DM and atherosclerosis-MSC post-MI. The signalling pathways driving the altered secretome of atherosclerosis- and T2DM-MSC are unknown. Specifically, the effect of IκB kinase β (IKKβ) modulation, a key regulator of inflammatory responses, on the immunopotency of MSCs from T2DM patients with advanced atherosclerosis has not been studied. Methods and results MSCs were isolated from adipose tissue obtained from patients with (i) atherosclerosis and T2DM (atherosclerosis+T2DM MSCs, n = 17) and (ii) atherosclerosis without T2DM (atherosclerosis MSCs, n = 17). MSCs from atherosclerosis+T2DM individuals displayed an inflammatory senescent phenotype and constitutively expressed active forms of effectors of the canonical IKKβ nuclear factor-κB transcription factors inflammatory pathway. Importantly, this constitutive pro-inflammatory IKKβ signature resulted in an altered secretome and impaired in vitro immunopotency and in vivo healing capacity in an acute MI model. Notably, treatment with a selective IKKβ inhibitor or IKKβ knockdown (KD) (clustered regularly interspaced short palindromic repeats/Cas9-mediated IKKβ KD) in atherosclerosis+T2DM MSCs reduced the production of pro-inflammatory secretome, increased survival, and rescued their immunopotency both in vitro and in vivo. Conclusions Constitutively active IKKβ reduces the immunopotency of atherosclerosis+T2DM MSC by changing their secretome composition. Modulation of IKKβ in atherosclerosis+T2DM MSCs enhances their myocardial repair ability. Graphical Abstract